This article originally posted 12 August, 2009 and appeared in Issue 481
Miscelaneous Issue 481
NEW PRODUCT!
Pitavastatin (Livalo, Kowa Pharmaceuticals), a HMG-CoA reductase inhibitor, was approved as a primary treatment for hypercholesterolemia and combined dyslipidemia. This new medication has a unique cyclopropyl group on its base structure, giving it the potential for greater LDL clearance and the reduction of plasma cholesterol. The manufacturer also said that pitavastatin is only minimally metabolized by the liver through the cytochrome P450 pathway.
See www.Kowapharma.com for more information.
Tools for your Practice: Foot Exam Flow Sheet
This is a great tool to use as a reminder for you to do a foot exam each time you see the patient. It can be used to motivate your patient to better self-care as they can see the progression of their neuropathy. Foot Exam Flow Sheet
Tolerx Phase 3 Study: DEFEND is a Phase 3 clinical study of otelixizumab in YOUNG ADULTS with newly diagnosed T1DM. Otelixizumab is an investigational agent, not yet approved by the FDA for marketing. DEFEND will determine if otelixizumab can help preserve the ability to make endogenous insulin and stop the destruction of the body's cells that make insulin (beta cells). You can find out more at: www.defendagainstdiabetes.com
DISCLAIMER: The content of this Website is independent of the views of our advertisers and sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.
Copyright @ 1999-2013 Diabetes In Control, Inc.. All rights reserved.
